The Eli Lilly brand seems on the corporate’s workplace in San Diego, California, U.S., Nov. 21, 2025.
Mike Blake | Reuters
Eli Lilly will acquire biotech firm Kelonia Therapeutics in a deal worth up to $7 billion, the company said Monday.
Lilly pays $3.25 billion upfront, and the remaining funds are contingent upon scientific, regulatory and business milestones, it stated. The transaction is predicted to shut in the second half of 2026.
Kelonia is creating know-how to reprogram sufferers’ T-cells contained in the physique so these cells can assault cancer, known as in vivo CAR-T. Current remedies require that work to be carried out exterior the physique, or ex vivo, a course of that includes harvesting cells, engineering them in a lab after which reintroducing them. While logistically intensive, the process has been profitable for blood cancers like a number of myeloma.
“It’s an intravenously delivered therapy, one time,” stated Jacob Van Naarden, president of Lilly oncology and head of company enterprise improvement. “It targets your body’s T-cells, transforms them into attacking the cancer in the body, and requires no preconditioning at all.”
Johnson and Johnson’s CAR-T remedy for a number of myeloma, Carvykti, accounted for $1.89 billion in gross sales final 12 months. Gilead just lately acquired accomplice Arcellx and its rival to J&J’s drug, known as anito-cel, for $7.8 billion.
Lilly’s Van Naarden known as Kelonia’s knowledge “nothing short of remarkable.”
“We’re going to be a player in hematology,” he stated. “It’s nice to have another medicine to go to those doctors with a medicine that can be used broadly, that isn’t relegated to academic medical centers who can do ex-vivo personalized cell therapy.”
